NCT03962114 is a Phase 2 clinical trial of Vitamin B3 in Ataxia Telangiectasia, sponsored by Radboud University Medical Center.

Who is sponsoring NCT03962114?

NCT03962114 is sponsored by Radboud University Medical Center.

What drugs are being tested in NCT03962114?

Interventions in NCT03962114: Vitamin B3.

What condition does NCT03962114 study?

NCT03962114 studies Ataxia Telangiectasia, ATM Gene Mutation.

Is NCT03962114 still recruiting?

NCT03962114 is currently completed. Last updated 25 July 2022.

Last reviewed 2022-07-25 · How we verify

NCT03962114

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Vitamin B3 in Patients With Ataxia Telangiectasia

Completed Phase 2 Last updated 25 July 2022

What this trial tests

Phase 2 trial testing Vitamin B3 in Ataxia Telangiectasia in 24 participants. Completed in 1 March 2020.

Timeline

18 March 2019

Primary endpoint
1 December 2019

1 March 2020

Quick facts

Lead sponsor	Radboud University Medical Center
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	18 March 2019
Primary completion	1 December 2019
Estimated completion	1 March 2020
Sites	1 location across Netherlands

Drugs / interventions tested

Vitamin B3 — full drug profile →

Conditions studied

Ataxia Telangiectasia — all drugs for Ataxia Telangiectasia →
ATM Gene Mutation — all drugs for ATM Gene Mutation →

Sponsor

Radboud University Medical Center

Who can join

2 and older, any sex, with Ataxia Telangiectasia or ATM Gene Mutation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical trial investigates the effects of nicotinamide riboside (vitamin B3) on the disease course of patients with ataxia telangiectasia. Patients will be treated during four consecutive months with nicotinamide riboside (25mg/kg/day), followed by a washout period of two months. Main study parameters/endpoints: Ataxia, dysarthria, quality of life, laboratory parameters.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical Evidence for Targeting NAD Therapeutically.
Radenkovic D, Reason, Verdin E. · · 2020 · cited 45× · PMID 32942582 · DOI 10.3390/ph13090247
The Potential Use of Metabolic Cofactors in Treatment of NAFLD.
Mardinoglu A, Ural D, Zeybel M, Yuksel HH, et al · · 2019 · cited 29× · PMID 31336926 · DOI 10.3390/nu11071578
Roles of NAD<sup>+</sup> in Health and Aging.
Lautrup S, Hou Y, Fang EF, Bohr VA. · · 2024 · cited 28× · PMID 37848251 · DOI 10.1101/cshperspect.a041193
Autophagic Organelles in DNA Damage Response.
Kim J, Lee S, Kim H, Lee H, et al · · 2021 · cited 17× · PMID 33912571 · DOI 10.3389/fcell.2021.668735
Targeting DNA damage in ageing: towards supercharging DNA repair.
Bujarrabal-Dueso A, Garinis GA, Robbins PD, Vijg J, et al · · 2025 · cited 8× · PMID 40506534 · DOI 10.1038/s41573-025-01212-6
Dysarthria in children and adults with ataxia telangiectasia.
Veenhuis SJG, van Os NJH, van Gerven MHJC, van Haaften L, et al · · 2021 · cited 7× · PMID 33521952 · DOI 10.1111/dmcn.14811
Variable Selection in Untargeted Metabolomics and the Danger of Sparsity.
Tinnevelt GH, Engelke UFH, Wevers RA, Veenhuis S, et al · · 2020 · cited 4× · PMID 33213095 · DOI 10.3390/metabo10110470

Verify or expand the search:

Other trials of Vitamin B3

Trials testing the same drug.

NCT05958277 — Vitamin B12 vs B3 for Nerve Regeneration and Functional Recovery After Pediatric Traumatic Brain Injury · Phase 3 · completed
NCT05119166 — International Milk Composition (IMiC) Consortium · active not recruiting
NCT03797469 — Nutritional Supplements and Performance During Visual Field Testing (B3 Vitamin) · NA · completed

Other recruiting trials for Ataxia Telangiectasia

Currently open trials in the same condition.

NCT04870866 — NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia · Phase 2 · active not recruiting

Other Radboud University Medical Center trials

Trials by the same sponsor.

NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03962114 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
Last refreshed: 25 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03962114.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing